Primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma that usually
occurs in HIV-positive patients and has a very poor prognosis with limited treatment options.
Prospective studies are lacking to define the standard of care for this disease, and various
case series report median survival at 6 months with anthracycline-based chemotherapy.
Reports of antiviral agents, immune modulators, and some targeted therapies are present in
the literature with variable results. Herein, we report a case of an elderly HIV-negative man …